📰 Programmed Cell Death News
Programmed Cell Death News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Programmed Cell Death. Real-time updates on events, politics, business and more.
April 19, 2024
Researchers have revealed the regulatory mechanism of a specific protein that plays a key role in balancing the immune response triggered by viral infections in mammal cells.
February 21, 2024
Announcing a new publication for Acta Materia Medica journal. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but pose a challenge of immune-related adverse events (irAEs), particularly endocrine toxicity, that can severely compromise patient well-being.
February 15, 2024
The skin cancer cells self-destructed, the study said.
February 14, 2024
Extracted from the core of sandalwood trees (santalum album tree), sandalwood oil has been used for many centuries by several cultures throughout the world for perfume, soaps, incense and candles.
February 14, 2024
The change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.
February 2, 2024
Cell death is fundamental to life and, thus, healthy aging. In the realm of cellular biology, ferroptosis (a form of programmed cell death) has emerged not only as a focal point of research for its potential in eliminating cancer cells, but also its role in a plethora of other diseases, including neurodegenerative diseases such as Alzheimer's disease, eye diseases such as Retinitis pigmentosa and age-related macular degeneration, as well as ischemia, cardiovascular disease, liver disease, ac...
January 20, 2024
Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer.
November 22, 2023
Using oncolytic viruses (OVs) in combination with nanomaterials as a novel approach to cancer treatment.
November 16, 2023
A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.